Acceleron Pharma Initiates Phase I Muscle Diseases Study
Acceleron Pharma has started a Phase I clinical study of ACE-031, its lead compound for treating diseases involving the loss of muscle mass and function.
The Phase I trial is a randomized, placebo-controlled single-dose, dose-escalating study to evaluate the safety and pharmacokinetics of ACE-031. This clinical trial is the first-in-human study in the global development of ACE-031 and will be conducted in Canada, said Acceleron Pharma.
According to the company, ACE-031, a soluble molecule based on the activin receptor type IIB, is a biologic therapeutic that inhibits signaling through the ActRIIB receptor. By blocking signaling though ActRIIB, ACE-031 increases muscle mass and strength.
Matthew Sherman, chief medical officer of Acceleron, said: “There is a tremendous unmet medical need to treat patients suffering from a wide array of diseases involving the loss of muscle strength and function. ACE-031 has the potential to be a very important new approach to treat these serious and life-threatening conditions.”